Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 13, 2026
Associations of Monocyte Glucocerebrosidase with Cognition and Cholinergic Innervation in GBA1 Parkinson's Disease
Sofie Slingerland, Sygrid van der Zee, Sven C D van Ijzendoorn, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 17, 2022
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment
Sygrid van der Zee, Prabesh Kanel, Marleen J J Gerritsen, et al.
European Journal of Hybrid Imaging
|
June 30, 2021
<sup>68</sup>Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas
Tessel M Boertien, Jan Booij, Charles B L M Majoie, et al.
NPJ Parkinson'S Disease
|
November 12, 2025
Modelling cholinergic and dopaminergic function over time in Parkinson's disease with and without GBA1 variants
Sofie Slingerland, Eline K R de Meyer, Harm J van der Horn, et al.
European Journal of Endocrinology
|
October 6, 2022
Compression of the optic chiasm is associated with reduced photoentrainment of the central biological clock
Tessel M Boertien, Eus J W Van Someren, Adriaan D Coumou, et al.
The Journal of Biological Chemistry
|
April 15, 2020
Functional diversity between HSP70 paralogs caused by variable interactions with specific co-chaperones
Despina Serlidaki, Maria A W H van Waarde, Lukas Rohland, et al.
BMJ Open
|
August 15, 2020
The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a <sup>68</sup><i></i> -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of <i></i> reotide on <i></i> umour size
Tessel M Boertien, Madeleine L Drent, Jan Booij, et al.
NPJ Parkinson'S Disease
|
October 10, 2022
Fecal microbiome alterations in treatment-naive de novo Parkinson's disease
Jeffrey M Boertien, Kirsi Murtomäki, Pedro A B Pereira, et al.
The Lancet Regional Health. Europe
|
July 29, 2024
Lanreotide versus placebo for tumour reduction in patients with a <sup>68</sup>Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment
Tessel M Boertien, Madeleine L Drent, Jan Booij, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 4, 2020
A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands
Jonas M den Heijer, Valerie C Cullen, Marialuisa Quadri, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 13, 2026
Associations of Monocyte Glucocerebrosidase with Cognition and Cholinergic Innervation in GBA1 Parkinson's Disease
Sofie Slingerland, Sygrid van der Zee, Sven C D van Ijzendoorn, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 17, 2022
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment
Sygrid van der Zee, Prabesh Kanel, Marleen J J Gerritsen, et al.
European Journal of Hybrid Imaging
|
June 30, 2021
<sup>68</sup>Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas
Tessel M Boertien, Jan Booij, Charles B L M Majoie, et al.
NPJ Parkinson'S Disease
|
November 12, 2025
Modelling cholinergic and dopaminergic function over time in Parkinson's disease with and without GBA1 variants
Sofie Slingerland, Eline K R de Meyer, Harm J van der Horn, et al.
European Journal of Endocrinology
|
October 6, 2022
Compression of the optic chiasm is associated with reduced photoentrainment of the central biological clock
Tessel M Boertien, Eus J W Van Someren, Adriaan D Coumou, et al.
The Journal of Biological Chemistry
|
April 15, 2020
Functional diversity between HSP70 paralogs caused by variable interactions with specific co-chaperones
Despina Serlidaki, Maria A W H van Waarde, Lukas Rohland, et al.
BMJ Open
|
August 15, 2020
The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a <sup>68</sup><i></i> -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of <i></i> reotide on <i></i> umour size
Tessel M Boertien, Madeleine L Drent, Jan Booij, et al.
NPJ Parkinson'S Disease
|
October 10, 2022
Fecal microbiome alterations in treatment-naive de novo Parkinson's disease
Jeffrey M Boertien, Kirsi Murtomäki, Pedro A B Pereira, et al.
The Lancet Regional Health. Europe
|
July 29, 2024
Lanreotide versus placebo for tumour reduction in patients with a <sup>68</sup>Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment
Tessel M Boertien, Madeleine L Drent, Jan Booij, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 4, 2020
A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands
Jonas M den Heijer, Valerie C Cullen, Marialuisa Quadri, et al.
Page
of 3